Venture Partners Vii Lpovp ... Net Worth

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... és Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.

What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Wolchko,
  President, Chief Executive Officer, Director
• Bahram Valamehr,
  Chief Development Officer
• Cindy Tahl,
  General Counsel and Corporate Secretary
• Daniel Shoemaker,
  Chief Scientific Officer
• J. Scott Wolchko,
  Founder, CEO, Pres & Director
• Dr. Bahram Valamehr Ph.D.,
  Chief R&D Officer
• Cindy R. Tahl,
  Gen. Counsel & Corp. Sec.
• Karin Jooss,
  Independent Director
• Shefali Agarwal,
  Director
• William Rastetter,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• John Mendlein,
  Independent Vice Chairman of the Board
• Robert Epstein,
  Independent Director
• Michael Lee,
  Independent Director
• Edward Dulac,
  Chief Financial Officer
• Robert Hershberg,
  Director
• Renee Leck,
  IR Contact Officer
• Yu-Waye Chu,
  Vice President - Clinical Development
• Sarah Cooley,
  Senior Vice President - Clinical Translation
• Dr. Mark Plavsic D.V.M., Ph.D.,
  Chief Technical Officer
• Dr. Yu-Waye Chu M.D.,
  Sr. VP of Clinical Devel.
• Jim Beitel M.B.A.,
  Sr. VP of Corp. Devel.
• Dr. Wen Bo Wang,
  Sr. VP of Technical Operations
• Edward J. Dulac III,
  CFO & Principal Accounting Officer
• Mark J Enyedy,
  Director
• Stewart Abbot,
  Chief Development Officer
• Chris Storgard,
  Chief Medical Officer
• Amir Nashat,
  Director
• Brian T. Powl,
  Chief Commercial Officer
• J Scott Wolchko,
  President and CEO
• Group, Llc Green Jeremy Red...,
  
• Pratik S Multani,
  Chief Medical Officer
• Peter D Flynn,
  See remarks
• Christian Weyer,
  See remarks
• Venture Fund Vi Lparch Vent...,
  
• Venture Partners Vii Lpovp ...,
  
• Venture Management Co. V, L...,
  
• Robert Nelsen,
  Director
• Associates V Lpvenrock Part...,
  
• Yuan Xu,
  
• Mark Plavsic,
  Chief Technical Officer
• Neelufar Mozaffarian,